Every 10-Q that SRX GLOBAL INC (SRXH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SRXH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SRXH filings page.
SRX Global Inc. (SRXH) reported higher net sales but continued losses for the three and nine months ended June 30, 2026, while transforming its business and balance sheet. Net sales from continuing operations rose to $3.4 million from $2.7 million a year earlier, and to $9.6 million for the nine-month period. Loss from continuing operations improved to $4.1 million from $6.9 million in the quarter, and to $19.1 million for nine months, but the company remains meaningfully unprofitable.
Cash and cash equivalents increased to $36.7 million (including restricted cash) from $1.3 million, and total assets reached $145.4 million, driven largely by an $80.0 million asset acquisition of EMJX, an AI-driven digital-asset treasury management platform, recorded as indefinite-lived intangible assets. Total liabilities were only $2.4 million, with prior convertible debt eliminated, resulting in stockholders’ equity of $143.0 million. The company now operates two segments: the legacy Halo pet products business and the new EMJX platform, and holds $2.1 million of Ethereum and other financial investments, introducing digital-asset and trading-related volatility. NYSE American halted trading on June 23, 2026 due to low share price, and a 1‑for‑60 reverse stock split became effective July 6, 2026. Management states it sees no material uncertainties about the company’s ability to continue as a going concern over the next 12 months.
SRx Health Solutions Inc. reports its first full quarter focused on premium pet products after exiting its Canadian healthcare business. For the three months ended March 31, 2026, net sales from continuing operations were $3.4 million, entirely from Digital, International, and Brick & Mortar pet channels, and the company recorded a net loss from continuing operations of $6.4 million (basic and diluted loss per share of $0.02).
Cash and cash equivalents rose to $20.5 million as of March 31, 2026 from $1.3 million at September 30, 2025, driven by equity financing, including common stock issued under a $1.0 billion equity line of credit and new Series B preferred stock and warrants. A $22.6 million ELOC Commitment Note is the company’s principal debt.
SRx also holds $8.3 million of crypto assets and actively trades derivatives and equity securities, introducing additional volatility. Management states that recent financings and cost actions support a going concern view, while an all‑stock $55 million EMJX transaction is expected to add digital-asset-related businesses.
SRx Health Solutions Inc. reported net sales of $2.8 million and a net loss of $8.6 million for the quarter ended December 31, 2025, as it refocuses on its Halo premium pet food business after exiting its Canadian healthcare operations.
Gross profit was $1.1 million on cost of goods sold of $1.8 million, but heavy selling, general and administrative expenses of $4.8 million and interest and other expenses, including a $3.1 million loss on extinguishment of debt and a $0.5 million loss on digital assets, drove the loss. Cash rose to $13.1 million, helped by new equity and preferred stock financings, while convertible debt totaled $21.0 million. The company also invested $8.5 million into crypto assets and subsequently raised about $29.1 million through its equity line, significantly increasing shares outstanding to 298.2 million as of February 11, 2026.
The condensed consolidated 10-Q shows SRx Health Solutions incurred a net loss of $15.1 million for the three months and $29.7 million for the nine months ended June 30, 2025, compared with losses of $3.1 million and $11.1 million in the prior-year periods. The company reports a working capital deficiency of $49.6 million and $67.7 million (two comparative periods), material impairments to customer-list intangibles, and goodwill-related adjustments tied to prior acquisitions.
Significant corporate actions include a reverse acquisition that made SRx Canada the accounting acquirer, a private placement raising $8.8 million (1,280,000 shares and 2,756,697 pre-funded warrants), issuance of shares for advisory and settlement purposes, repurchase activity (76,800 shares repurchased in the period) and the subsequent filing for creditor protection under CCAA by the Canadian operating subsidiary, which led to a write-off of a prepaid amount. The company also has convertible and secured notes outstanding and a senior secured convertible note financing referenced as a subsequent event.